Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan Gu

Showing results (1061-1070 of 1,076) with videos related to

Pageof 108
Sort By:
Nature Communications|January 9, 2024
Dual-plasmonic Au@Cu<sub>7</sub>S<sub>4</sub> yolk@shell nanocrystals for photocatalytic hydrogen production across visible to near infrared spectral regionChun-Wen Tsao, Sudhakar Narra, Jui-Cheng Kao, et al.
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinaseVictor J Cee, Alan C Cheng, Karina Romero, et al.
Journal of Medicinal Chemistry|December 4, 2013
Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitorsZihao Hua, Howard Bregman, John L Buchanan, et al.
Journal of Medicinal Chemistry|August 19, 2007
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitorsMichele H Potashman, James Bready, Angela Coxon, et al.
Respiratory Research|December 3, 2022
The Establishment of China Bronchiectasis Registry and Research Collaboration (BE-China): Protocol of a prospective multicenter observational studyYong-Hua Gao, Hai-Wen Lu, Bei Mao, et al.
Journal of Medicinal Chemistry|January 27, 2007
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinaseVictor J Cee, Brian K Albrecht, Stephanie Geuns-Meyer, et al.
Liver Cancer|June 3, 2026
Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety StudyJing-Kun Chen, Jia-Liang Wei, Zhen-Dong Yang, et al.
Journal of Medicinal Chemistry|January 27, 2007
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitorBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
Journal of Medicinal Chemistry|February 19, 2008
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
Pageof 108

Showing results (1061-1070 of 1,076) with videos related to

Sort By:
Pageof 108
Nature Communications|January 9, 2024
Dual-plasmonic Au@Cu<sub>7</sub>S<sub>4</sub> yolk@shell nanocrystals for photocatalytic hydrogen production across visible to near infrared spectral regionChun-Wen Tsao, Sudhakar Narra, Jui-Cheng Kao, et al.
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinaseVictor J Cee, Alan C Cheng, Karina Romero, et al.
Journal of Medicinal Chemistry|December 4, 2013
Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitorsZihao Hua, Howard Bregman, John L Buchanan, et al.
Journal of Medicinal Chemistry|August 19, 2007
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitorsMichele H Potashman, James Bready, Angela Coxon, et al.
Respiratory Research|December 3, 2022
The Establishment of China Bronchiectasis Registry and Research Collaboration (BE-China): Protocol of a prospective multicenter observational studyYong-Hua Gao, Hai-Wen Lu, Bei Mao, et al.
Journal of Medicinal Chemistry|January 27, 2007
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinaseVictor J Cee, Brian K Albrecht, Stephanie Geuns-Meyer, et al.
Liver Cancer|June 3, 2026
Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety StudyJing-Kun Chen, Jia-Liang Wei, Zhen-Dong Yang, et al.
Journal of Medicinal Chemistry|January 27, 2007
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitorBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
Journal of Medicinal Chemistry|February 19, 2008
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
Pageof 108